INHA | Inhibin, alpha | Predicted secreted proteins
| | | | | Tissue enhanced |
IRS4 | Insulin receptor substrate 4 | Predicted secreted proteins
| | | | | Tissue enhanced |
KCNMB2 | Potassium large conductance calcium-activated channel, subfamily M, beta member 2 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
KCNT2 | Potassium channel, subfamily T, member 2 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
LAMP5 | Lysosomal-associated membrane protein family, member 5 | Predicted membrane proteins
| | | | | Tissue enhanced |
LINC00908 | Long intergenic non-protein coding RNA 908 | | | | | | Tissue enhanced |
LPAR4 | Lysophosphatidic acid receptor 4 | G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
LRRC17 | Leucine rich repeat containing 17 | Predicted secreted proteins
| | | | | Tissue enhanced |
MCC | Mutated in colorectal cancers | | | | | | Tissue enhanced |
MEX3A | Mex-3 RNA binding family member A | | | | | | Tissue enhanced |
MKX | Mohawk homeobox | Transcription factors
| | | | | Tissue enhanced |
NAV3 | Neuron navigator 3 | Cancer-related genes Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
NDP | Norrie disease (pseudoglioma) | Disease related genes Predicted secreted proteins
| | | | | Tissue enhanced |
NDST4 | N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 4 | Enzymes
| | | | | Tissue enhanced |
NGF | Nerve growth factor (beta polypeptide) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Plasma proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
NLGN4X | Neuroligin 4, X-linked | Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
NR2F2 | Nuclear receptor subfamily 2, group F, member 2 | Nuclear receptors Transcription factors
| | | | | Tissue enhanced |
NRG2 | Neuregulin 2 | Cancer-related genes Predicted membrane proteins
| | | | | Tissue enhanced |
NRK | Nik related kinase | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
NTF3 | Neurotrophin 3 | Cancer-related genes Predicted secreted proteins
| | | | | Tissue enhanced |
OXTR | Oxytocin receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
PABPC5 | Poly(A) binding protein, cytoplasmic 5 | | | | | | Tissue enhanced |
PCDH11X | Protocadherin 11 X-linked | Predicted membrane proteins
| | | | | Tissue enhanced |
PDGFD | Platelet derived growth factor D | Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
PDGFRA | Platelet-derived growth factor receptor, alpha polypeptide | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
PEG3 | Paternally expressed 3 | Transcription factors
| | | | | Tissue enhanced |
PLA2G5 | Phospholipase A2, group V | Disease related genes Enzymes Potential drug targets Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
PLCXD3 | Phosphatidylinositol-specific phospholipase C, X domain containing 3 | | | | | | Tissue enhanced |
PRSS35 | Protease, serine, 35 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
RASL11B | RAS-like, family 11, member B | | | | | | Tissue enhanced |
RBP1 | Retinol binding protein 1, cellular | | | | | | Tissue enhanced |
RP11-366L20.2 | Uncharacterized protein | | | | | | Tissue enhanced |
RP6-24A23.6 | Uncharacterized protein | | | | | | Tissue enhanced |
SCN7A | Sodium channel, voltage-gated, type VII, alpha subunit | Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
SCUBE1 | Signal peptide, CUB domain, EGF-like 1 | Predicted secreted proteins
| | | | | Tissue enhanced |
SERHL2 | Serine hydrolase-like 2 | Plasma proteins
| | | | | Tissue enhanced |
SGCZ | Sarcoglycan, zeta | Cytoskeleton related proteins Predicted membrane proteins
| | | | | Tissue enhanced |
SNCAIP | Synuclein, alpha interacting protein | Disease related genes
| | | | | Tissue enhanced |
STXBP5L | Syntaxin binding protein 5-like | | | | | | Tissue enhanced |
TCF23 | Transcription factor 23 | Transcription factors
| | | | | Tissue enhanced |
TENM4 | Teneurin transmembrane protein 4 | Predicted membrane proteins
| | | | | Tissue enhanced |
TMEM221 | Transmembrane protein 221 | Predicted membrane proteins
| | | | | Tissue enhanced |
TMEM255A | Transmembrane protein 255A | Predicted membrane proteins
| | | | | Tissue enhanced |
TRO | Trophinin | Cancer-related genes Plasma proteins
| | | | | Tissue enhanced |
TYRO3 | TYRO3 protein tyrosine kinase | Cancer-related genes Enzymes Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
VIT | Vitrin | Predicted secreted proteins
| | | | | Tissue enhanced |
VLDLR | Very low density lipoprotein receptor | Disease related genes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
VSX1 | Visual system homeobox 1 | Disease related genes Transcription factors
| | | | | Tissue enhanced |
VWC2 | Von Willebrand factor C domain containing 2 | Predicted secreted proteins
| | | | | Tissue enhanced |
VWCE | Von Willebrand factor C and EGF domains | Predicted secreted proteins
| | | | | Tissue enhanced |